

Benno Kreuels^{1,2,3}, Alexander J. Stockdale^{4,5}, Isaac T. Shawa^{3,4}, Niza M. Silungwe⁴, Karen Chetcuti³, Elizabeth Joeke^{4,6}, Blessings Mbale⁴, Jane Mallewa³, Egbert Tannich¹, Christina Weiler-Normann², Marc Luetgehetmann², Peter Finch³, Emma C. Thomson⁷, Anna Maria Geretti⁸, Melita A. Gordon ^{4,5}

1. Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany; 2. University Medical Centre Hamburg-Eppendorf, Hamburg, Germany; 3. Kamuzu University of Health Sciences, Blantyre, Malawi; 4. Malawi-Liverpool-Wellcome Trust Programme, Blantyre, Malawi; 5. University of Liverpool, United Kingdom; 6. Royal Liverpool Hospital, Liverpool, United Kingdom; 7. Center for Virus Research, Glasgow, United Kingdom; 8. PTV University of Rome Tor Vergata, Rome, Italy

Background	
<ul style="list-style-type: none">African countries experience the highest age-standardised mortality from liver disease globallyDue to limitations in laboratory diagnostics and imaging, the relative importance of different causes of liver disease in Africa is largely unknownMore data is needed on outcomes and potential causes of liver disease to inform effective public health strategiesThus, we studied patients with cirrhosis and hepatocellular carcinoma (HCC) presenting to a tertiary hospital in southern Malawi to ascertain aetiology and outcomes, and develop intervention strategies	

Study recruitment	
708 screened	
373 eligible of which 272 consented	
216 included	
138 with cirrhosis	78 with HCC

Results	
Causes	Outcomes
<ul style="list-style-type: none">Hepatitis B was the main attributable cause of cirrhosis (PAF 25.5% (95% CI:17.1–33.1)) and HCC (PAF 73.2% (61.0–81.6))HIV was the second most important attributable factor (PAF 23.6% (13.5–32.5) for cirrhosis and 20.2% (7.4–31.2) for HCC)For cirrhosis, autoimmune hepatitis (4%), primary biliary cholangitis (3%) and hepatitis C (1%) were uncommon causes and 16% showed ultrasonographic features of schistosomiasisNo patients were viraemic for hepatitis D or E	<ul style="list-style-type: none">Patients with HCC were median 40 years old (IQR 35-50) and median survival was 40 days (95% CI:30–51)Among patients with cirrhosis, 60% remained alive in care at 6 months

Methods		Conclusion	
<p>Study design</p> <ul style="list-style-type: none">Observational cohort and community case-control study <p>Study setting and population</p> <ul style="list-style-type: none">Patients with suspected liver disease presenting to Queen Elizabeth Central Hospital in Blantyre, MalawiCommunity control group from Ndirande, Blantyre <p>Data collection</p> <ul style="list-style-type: none">Prospective screening for 18 months, with follow-up for 6 monthsRecruitment of community controls for hepatitis B/C from a serological survey randomly selected from a demographic census <p>Data analysis</p> <ul style="list-style-type: none">Estimation of population attributable fractions (PAF) of contributing factors for cirrhosis and HCC6-month mortality among patients with cirrhosis/HCC was modelled using a Cox proportional hazards regression		<p>Causes of liver disease in southern Malawi</p> <ul style="list-style-type: none">Leading causes: Hepatitis B and HIVSecondary causes: Alcohol, autoimmune liver disease and smokingFurther investigation is needed for the role of schistosomiasis and its contribution to liver disease <p>Need for improved diagnosis and earlier presentation</p> <ul style="list-style-type: none">HCC and cirrhosis are diagnosed at an advanced stage, with an abysmal prognosisThere is an urgent unmet need for expanded community HBV screen-and-treat programmes to prevent rising liver-related diseases and potentially improve outcomes	
		<p>Kaplan Meier survival curves: 6-month outcomes among with cirrhosis and HCC</p>	